![]() | Fiscal NoteH.B. 598 2026 General Session Uterine Fibroid Amendments by Dominguez, Rosalba | ![]() |
| Ongoing | One-time | Total | |
|---|---|---|---|
| Net GF/ITF/USF (rev.-exp.) | $(119,100) | $(37,500) | $(156,600) |
| Revenues | FY2026 | FY2027 | FY2028 |
| Total Revenues | $0 | $0 | $0 |
Enactment of this legislation likely will not materially impact state revenue.
| Expenditures | FY2026 | FY2027 | FY2028 |
| General Fund | $0 | $119,100 | $119,100 |
| General Fund, One-time | $0 | $37,500 | $37,500 |
| Total Expenditures | $0 | $156,600 | $156,600 |
Enactment of this legislation could cost the Department of Health and Human Services $119,100 ongoing General Fund and $37,500 one-time General Fund in FY 2027 and FY 2028. These would cover staffing costs for gathering data and generating reports. Additionally, it would cover pass through funds for research purposes.
| FY2026 | FY2027 | FY2028 | |
| Net All Funds (rev-exp) | $0 | $(156,600) | $(156,600) |
Enactment of this legislation likely will not result in direct, measurable costs for local governments.
Enactment of this legislation likely will not result in direct expenditures from tax or fee changes for Utah residents and businesses.
Enactment of this legislation likely will not change the regulatory burden for Utah residents or businesses.
This bill does not create a new program or significantly expand an existing program.

